US2021346358A1PendingUtilityA1
Compounds and methods for kinase modulation, and indications therefor
Est. expiryJul 17, 2027(~1 yrs left)· nominal 20-yr term from priority
Inventors:Guoxian WuJiazhong ZhangYong-Liang ZhuChao ZhangPrabha N. IbrahimSongyuan ShiWayne SpevakDean R. ArtisJames Tsai
A61P 25/02A61K 31/4545A61P 25/04A61P 9/10A61P 37/08A61P 13/08C07D 239/48A61K 31/44C07D 215/14A61P 43/00A61P 35/02A61P 25/14A61P 17/04A61K 31/47A61P 37/00A61P 3/04C07D 215/12C07D 231/40C07D 285/16A61P 11/02A61P 7/00C07D 401/12A61P 29/00A61P 11/06A61P 17/00A61P 19/10A61K 31/444C07D 417/04A61P 37/06C07D 215/20C07D 471/04A61K 31/415A61P 31/20C07D 215/38A61P 25/16A61P 21/04A61K 31/4436A61P 9/08C07D 213/74C07D 409/12A61K 31/505A61P 17/06C07D 405/12C07D 213/75C07D 285/135C07D 261/14A61P 3/00A61P 9/04A61K 31/433A61P 5/14A61P 25/28A61K 31/437A61P 15/00A61P 13/12A61P 35/04A61P 31/14A61P 15/10A61P 31/16A61P 7/02C07D 263/48A61P 19/08A61K 45/06A61P 19/00C07D 239/49A61P 27/02A61K 31/5377A61P 1/18A61K 31/4439A61P 3/10A61P 1/16C07D 417/12C07D 213/82C07D 213/76A61P 3/06A61P 1/04A61K 31/42A61P 35/00A61P 19/02A61P 17/14A61P 11/00A61K 31/549A61K 31/506A61P 5/00A61P 25/00A61P 17/02A61P 31/12A61P 21/00A61P 25/06A61P 31/04A61P 9/00
80
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . A compound of formula (Ia):
or a pharmaceutically acceptable salt thereof,
wherein:
L 1 is a bond or —N(H)C(O)—;
each R 1 is R 16 ;
R 2 is hydrogen or halogen;
R 3 is lower alkyl or phenyl substituted with one or more substituents selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, and fluoro substituted lower alkylthio;
R 4 is hydrogen;
m is 0, 1, 2, or 3;
Ar is
each X is independently N or CH, provided that at least one and no more than 2 of X in any ring is N;
Y is NH, O, or S;
each R 16 is independently lower alkyl or heteroaryl, wherein the heteroaryl is optionally substituted with one or more substituents selected from the group consisting of —OH, —NH 2 , —CN, —NO 2 , —C(O)—OH, —S(O) 2 —NH 2 , —C(O)—NH 2 , —O—R 18 , —S—R 18 , —N(R 19 )—R 18 , —N(R 19 )—C(O)—R 18 , —N(R 19 )—S(O) 2 —R 18 , —S(O) 2 —R 18 , —C(O)—R 18 , —C(O)—O—R 18 , —C(O)—N(R 19 )—R 18 , —S(O) 2 —N(R 19 )—R 18 , halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino;
R 18 is lower alkyl; and
R 19 at each occurrence is hydrogen or lower alkyl.
3 . The compound of claim 2 , wherein R 2 is hydrogen.
4 . The compound of claim 2 , wherein R 2 is halogen.
5 . The compound of claim 2 , wherein R 3 is phenyl substituted with one or more fluoro.
6 . A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or excipient.Join the waitlist — get patent alerts
Track US2021346358A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.